Compare AbbVie Inc (ABBV) vs British American Tobacco PLC (BTI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs British American Tobacco PLC — how do they compare? AbbVie Inc trades at $253.75 (market cap $449.91B), while British American Tobacco PLC trades at $61.69 (market cap $132.11B). The key difference: AbbVie Inc is far larger — about 3.4× British American Tobacco PLC's market cap, and British American Tobacco PLC pays the higher dividend (5.4%). Which is the better fit depends on your goals.
| ABBV | BTI | |
|---|---|---|
Market Cap | $449.91B | $132.11B |
Sector | Health | Consumer Staples |
52-Week High | $261.07 | $66.70 |
52-Week Low | $184.85 | $47.93 |
Enterprise Value | $513.38B | $173.34B |
Dividend Yield | 2.72% | 5.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
British American Tobacco (BTI) trades at $61.80, up 0.05% on the day, with a bullish technical signal from moving averages and strong support at $61. The company shows robust profitability with a 30.32% net income margin and a 15.74% ROE, though revenue declined to $25.87B in 2024. Recent news highlights a major restructuring with 5,500 job cuts to drive cost savings and growth in non-traditional products like Velo nicotine pouches (Reuters, 2026-06-29).
BTI offers a compelling value with a P/E of 13.34 and a 5%+ dividend yield, supported by 66.7% analyst buy ratings. Key risks include regulatory pressures from the FDA's proposed oversight of foreign tobacco makers (Reuters, 2026-06-26) and volatile earnings, as seen in a 2023 net loss. The stock's outlook is positive for income-focused investors, balancing high margins with transformation efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About British American Tobacco PLC
Following the acquisition of Reynolds American, British American Tobacco is neck-and-neck with Philip Morris International to be the largest listed global tobacco company--slightly larger than PMI on net revenue, but slightly smaller on total tobacco volume. British American's Global Drive Brands are Dunhill, Kent, Pall Mall, Lucky Strike, and Rothmans, and it also owns Newport and Camel in the U.S. The firm also sells vapor e-cigarettes, including its Vype brand, heated tobacco, with Glo, as well as roll- your-own and smokeless tobacco products. The company holds 31% of ITC Limited, the leading Indian cigarette-maker.
Read more on BTI →
